In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 ...

A third-generation PCSK9 inhibitor, lerodalcibep is indicated as an adjunct to diet and exercise to reduce LDL cholesterol in ...

"Our goal in the LATIFY trial was to reinvigorate the immune response of patients with lung cancer whose tumours stopped ...

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...

Clinicians Laura Huppert, Kelsey Natsuhara, and Magdelena Ford discuss the evidence, challenges, and real-world considerations guiding CDK4/6 inhibitor management in the adjuvant setting.

A pharmacy-based intervention may help increase SGLT2 inhibitor use for patients with type 2 diabetes and chronic kidney ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopenia Novel treatment targets BTK through multi-immune modulation to help address the underlying causes of ITP ...

Within the 48-week treatment window, the Bruton’s tyrosine kinase (BTK) inhibitor triggered a 57.1% improvement in patients’ ...

Financing includes participation from leading institutional investors including Janus Henderson Investors, Brahma Capital, Biotrack Capital, Cormorant Asset Management, OrbiMed, Plaisance Capital ...

Abstract Aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) were first recognized as a distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole.